Pharma News

PLx Pharma Inc a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform to provide more effective and safer products, with its lead products VAZALORE 325 mg and VAZALORE 81 mg ,referred to together as VAZALORE, announced that three stock-keeping units of VAZALORE, the first and only U.S. Food and Drug Administration approved liquid-filled aspirin capsules, will be available in over 8,000 Walgreens stores nationwide later in August. Walgreens is a global leader in retail pharmacy.

Adenovirus vaccine vectors, such as the ChAdOx1 nCov-19 construct which has risen to prominence as a major vaccine for COVID-19, may generate robust long-term immune system responses, according to scientists from the Universities of Oxford and the Cantonal Hospital St.Gallen, Switzerland.

Writing in the journal Nature Immunology, they detail an investigation into one of the key features of adenovirus vaccines – their ability to generate strong and sustained populations of the ‘killer’ T-cell element of the immune system.

Improvisation of the Pharmacopeia and capacity building with CSIR and IITs are the major focus areas for promoting Innvoations in AYUSH Sector said by Dr. Manoj Nesari, Advisor, Ministry of AYUSH, Govt. of India.

AYUSH Committee, PHDCCI organized a Webinar on Innovation & Entrepreneurship in AYUSH Sector- Role of Industry and Govt. of India on 15th July 2021.

BONE THERAPEUTICS the cell therapy company addressing unmet medical needs in orthopedics and other diseases provides an update on its two leading ongoing clinical studies.

These studies are the pivotal Phase III clinical trial with Bone Therapeutics’ enhanced viscosupplement, JTA-004, targeting osteoarthritic knee pain, and the Phase IIb study with its allogeneic cell therapy product, ALLOB, in patients with difficult-to-heal tibial fractures.

Valneva SE a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc announced that they have completed recruitment for the Phase 2 trial, VLA15-221, of Lyme disease vaccine candidate, VLA15. The trial builds on previous positive Phase 2 trials and includes both adult and pediatric participants with the aim to support acceleration of the vaccine candidate’s pediatric program.

Celltrion Group today announced new results from an in vivo efficacy study showing that regdanvimab, CT-P59 has a strong neutralising effect against the rapidly spreading Delta variant, B.1.617.2, first identified in India.

According to the World Health Organization, WHO, the Delta variant has been reported in 96 countries becoming the most common variant.1

Affinivax, Inc and Astellas Pharma Inc announced results from the Phase 2 clinical trial of ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae. Developed using Affinivaxs proprietary MAPS (Multiple Antigen-Presenting System) platform technology, ASP3772 is designed to offer both B-cell (antibody) and T-cell immune protection against Streptococcus pneumoniae. ASP3772 includes 24 pneumococcal polysaccharides, as well as two conserved pneumococcal proteins. The results from the Phase 2 clinical trial demonstrated that ASP3772 was well tolerated.

The Ministry of Earth Sciences National Institute of Ocean Technology has entered into an agreement with Karnataka-based Cosmos Biotech LLP for the transfer of technology for the production of Ecotine, a key ingredient of skin care and sun protection products.

American Gene Technologies announced that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGTs HIV cure program without modification, after safety analysis of the participants data revealed no adverse effects from the treatment. AGTs Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease, is designed to induce durable viral suppression by delivering therapeutic genes to the recipient's immune cells. The cells are collected by leukapheresis, modified outside the body, then re-infused.